Project
ETOP 25-23 ADOPT-lung
Ongoing - recruitment active · 2024 until 2029
Früh Martin, Harder Anja, Müller Fiona
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Ongoing - recruitment active
Start Date
2024
End Date
2029
Financing
Industry
Labels
lung cancer
Brief description/objective
An international, multicentre, open-label randomised
phase III trial to evaluate the benefit of adding
adjuvant durvalumab after neoadjuvant chemotherapy
plus durvalumab in patients with stage IIB-IIIB (N2)
resectable NSCLC